Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone

NCT01882361 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT01882361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01882361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
Lead sponsor
University of Pennsylvania
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2013
Completion date
July 31, 2020
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus, opiate dependence